$ADT

Morgan Stanley Raises ADT Price Target, Keeps Equal Weight Rating

Morgan Stanley raised its ADT Inc. (NYSE:ADT) price target to $7.50 from $7, keeping an Equal Weight rating, after ADT reported Q1 2026 results. The firm cited better-than-expected margins and free cash flow, though some gains reflected timing. Q1 revenue rose 1% year over year to $1.3 billion.

Original reporting
Published May 30, 2026, 6:30 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai May 30, 2026, 6:53 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Morgan Stanley Raises ADT Price Target, Keeps Equal Weight Rating — source image
Decision brief

The 30-second read

$ADTBullishMed
01

Why it matters

The PT increase provides valuation support, but the investment case hinges on whether DIY ADT Blu and ADT+ feature expansion translate into measurable subscriber stabilization.

02

Market read

A sell-side valuation update tied to Q1 margin/FCF beats and a product catalyst, with subscriber headwinds still a key risk.

03

What to watch

DIY ADT Blu subscriber tailwind is prospective; traders may need confirmation in subsequent subscriber adds/ARPU rather than rely on near-term margin optics.

Relevance 8/10Novelty 4/10Timing: pre-market today (published 2026-05-30 06:30 UTC)

Background

Morgan Stanley’s May 1 update follows ADT’s Q1 2026 print and centers on profitability/FCF versus subscriber growth headwinds.

Company-level read

Ticker impact

$ADTBullishMedium confidence
Context

Morgan Stanley raised ADT’s price target to $7.50 after Q1 2026 results showed better-than-expected margins and free cash flow.

Expected impact

Near-term bias to stabilize/strengthen sentiment if traders view the Q1 margin/FCF beat as durable.

Evidence & confidence

The article is a sell-side PT change tied to specific Q1 datapoints (margins/FCF) and a product catalyst (DIY ADT Blu), but it also flags subscriber headwinds, limiting upside conviction.

Market effects

Reinforces the narrative that security/home-automation providers can see margin/FCF support even with subscriber softness, if product/feature launches gain traction.

Primarily US residential/small-business security market sentiment.

Limited—company-specific analyst update with no direct global macro linkage.

Counterpoint

If margin/FCF improvement was largely timing-driven, the PT hike may fade once underlying subscriber trends reassert.

Key entities

  • ADT Inc.

    US residential and small-business security and smart home solutions provider; subject of the analyst price-target change.

  • Morgan Stanley

    Raised ADT’s price target to $7.50 while keeping an Equal Weight rating.

Related articles

$ADTMedAI 8/10

Consumer Discretionary - Specialized Consumer Services Stocks Q2 Results: Benchmarking ADT (NYSE:ADT)

H&R Block (HRB) reported Q2 revenue of $1.14B, up 3% YoY, beating estimates and raising guidance. Its stock rose 11.9%. Matthews (MATW) reported a 29.6% YoY revenue decline, missing estimates, and its stock fell 20%. Pool (POOL) met revenue expectations but missed EPS estimates, with its stock unchanged. Carriage Services (CSV) reported flat revenue, missing estimates, and its stock dropped 16.8%.

$ADTMed

ADT Inc. (ADT): Results of Operations and Financial Condition

ADT Inc. (ADT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 ADT Reports Second Quarter 2026 Results Continued strong cash generation GAAP Operating Cash Flows up 18%, Adjusted Free Cash Flow (including swaps) up 48% Returned $684 million to shareholders through share repurchases and dividends in first half of the year Raising

$RIVNMed

Why is Rivian stock sliding today?

Rivian's stock fell 6.8% to $15.66 after CFO Claire McDonough announced her departure in October 2026 to join GE Vernova. The company is scaling production of the R2 SUV, key to its profitability. McDonough's tenure included Rivian's $13.7B IPO and a $5.8B investment from Volkswagen. The broader market was slightly lower, with EV peers unaffected.

$CYTKMedAI 8/10

Why Cytokinetics (CYTK) Stock Is Down Today

Cytokinetics (CYTK) shares fell 7.7% following the release of full Phase 3 ACACIA-HCM trial data for aficamten, which met primary endpoints but showed treatment interruptions and adverse events. The next milestone is a 2026 FDA filing. Investors may have already priced in positive topline results from May.

$ACMMed

Why is Aecom Technology stock climbing today?

AECOM stock rose 2.7% after a glacier-collapse flood in Nepal, with estimated rebuilding costs of $5 billion. The company, with a $21 billion backlog, is seen as a potential beneficiary for reconstruction contracts. This follows a recent earnings miss and a price target cut by Baird to $73. The broader market's positive trend also supports infrastructure-linked stocks.